1770420078
Melanoma Matters

Advertise on podcast: Melanoma Matters

Rating
★★★★☆
4
from
4 reviews
This podcast has
95 episodes
Language
English
Explicit
No
Date created
2024/09/25
Latest episode
2026/10/16
Average duration
26 min.
Release period
21 days

Description

From the UK to the USA - Melanoma Matters is on a mission! Hosts James Larkin and Sapna Patel are spreading the word on melanoma, one podcast at a time. Tune in for a critical review of the literature and a discussion of how we incorporate the data into our practices...across the pond(s). #MelanomaMatters video podcast

Unlock Melanoma Matters podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Melanoma Matters podcast


Preview of a PREVIEW
2026/10/16
ADCs are coming in melanoma and James is stunned into silence for 45s
Ep 89: PREVIEW ESMO Annual Meeting: 2026 Madrid
2026/10/16
James and Sapna discuss all the meanings of the word "pike" and preview the presentations they are looking forward to at the 2026 ESMO Annual Congress from the Melanoma and Skin Tumours track. Sapna wants to see all of you at the poster session on Saturday 24 October 2026 from 1200 to 1245h Nos vemos pronto en Madrid!
Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)
2026/09/01
Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell Short Hobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunotherapy against anti PD 1 monotherapy. The discussion focuses on why toxicity rises without clear efficacy gains, and what these results mean for adjuvant and neoadjuvant strategy going forward. James Larkin and Sapna Patel also dig into a bigger question: if combination therapy helps in metastatic disease, why does it seem to lose its edge in microscopic or adjuvant disease? Key topics In this episode, the hosts review three adjuvant trials: CheckMate 915Relativity 098KeyVibe 010 The bottom line across all three studies is negative efficacy for combination therapy versus monotherapy in the adjuvant setting.The conversation emphasizes toxicity and discontinuation as a major issue with combination arms, especially when patients stop early because of adverse effects rather than progression.They revisit the CheckMate 915 dosing question, noting that the ipilimumab exposure in that study was much lower than the classic EORTC adjuvant regimen.The hosts compare dosing intensity and cumulative dose across adjuvant and metastatic settings, including the idea that dose density may matter as much as total dose. The episode raises a larger strategic question for melanoma care:Should adjuvant therapy remain monotherapy?Should neoadjuvant treatment replace some adjuvant use?Should patients receive both?
Ep 86: Teaser Tudriqev (RP1) FDA Approval
2026/08/25
James asks the big question
Ep 87: INTerpath-001 Press Release - August 2026
2026/08/25
In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualized neoantigen therapy plus pembrolizumab for resected stage IIB to IV melanoma. No data were shared, only descriptive findings of "statistically signficant" and "clinically meaningful" results. As James puts it, one of these is binary, the other is subjective.
Ep 86: Tudriqev (RP1) FDA Approval
2026/08/25
In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-V They discuss the FDA Cell and Gene Therapy Advisory Committee's review of the single-arm IGNYTE data and key issues around if this represents a local or systemic therapy, the maths around calculating response rate, and importantly how to identify optimal tumor characteristics for this treatment - what Sapna calls "Larkin-izing" the data. It's a long episode with a short fact check and lots of shoutouts to Kevin Harrington for his work in this space.
Ep 85: Surgical considerations for TIL
2026/07/28
In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of interest include optimal anatomic site(s), size (is bigger always better?), number of lesions and which of these components comprise a successful ex vivo expansion of TIL
Ep 84: Merlin CP-GEP and Castle i31-SLNB tests
2026/07/24
In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on gene expression profile tests—Merlin 001 study of CP-GEP and Castle i31-SLNB —used to predict sentinel lymph node positivity in melanoma. James and Sapna discuss the study designs, clinical utility, and implications for clinical management.
Ep 83: Guest Megan Othus and Time of Day Administration
2026/06/24
James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG. Megan talks about growing up in the PNW and going East to get back West. She helps us digest the time of day analyses and some of the missing analyses that should have been shown in the papers published to date. She teaches us about confounders, accounting for multiple comparisons, and guarantee time bias.
Ep 82: Best of ASCO: 2026
2026/06/13
In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications. They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes. Studies discussed include: OptimUM-02 phase 2/3 trial for metastatic uveal melanoma ADAM phase 3 trial for MCC5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)Pilot neoadjuvant studies (NeoReNi, NeoINR)Time of day of infusion and immunotherapy efficacy
Live from ASCO 2026: a preview
2026/06/01
James & Sapna sent a brief message from ASCO 2026 about what they are looking forward to hearing at the meeting. OptimUM-02 ADAM KN-942 Neoadjuvant pilot studies ... and more
Ep 81: IGNYTE trial (RP1 + nivo)
2026/02/13
SummaryThe conversation covers the published data from the IGNYTE study - RP1 + nivolumab: response rate and safety profile, RNA-seq analysis, and toxicity. The key takeaways include insights into clinical trial interpretation and treatment efficacy (and incorrect graphs).Takeaways Clinical Trial DataTreatment Efficacy Chapters 00:00 Introduction to IGNYTE Study14:04 Response Rate and Safety Profile25:17 RNA-seq Analysis and Toxicity
Ep 80: 2025 Holiday Special
2025/12/30
Summary Happy Holidays and Festive Season Everyone! In this episode of Melanoma Matters, hosts Sapna Patel and James reflect on their "cultural" experiences over the past year, discussing movies, music, books, plays, and television shows. They share personal anecdotes about memorable trips, culinary highlights, gym feats, and their podcasting journey, while also looking ahead to their goals and aspirations for 2026. Keywords movies, music, books, plays, television, travel, culinary, podcast, goals, aspirations, Happy Holidays, 2025, reflections, best Takeaways "Culture" James and Sapna read a lot of books. Theatrical performances can be a delightful family experience - James highly recommends Matilda. There is lots of television watching on both sides of the pond. Traveling memories in 2025. Culinary adventures include Ottolenghi in Richmond. Podcasting is fun when you do it with your best friend. Chapters 00:00 Festive Reflections and Year-End Special 02:50 Movies and Theater Experiences 09:32 Books he read & bought for others to read 12:29 Books she read or audio'ed 15:56 TV shows we watched in 2025 20:38 Travel Highlights of the Year 22:50 Culinary Adventures and Memorable Meals 24:28 Podcast Highlights and Notable Guests 32:34 Gym Goalz & PBs
Ep 79: coBRIM, COMBI-d 5-year follow-up
2025/12/29
Summary In this episode of Melanoma Matters, James awaits an invitation to a film premiere (The Penguin Lessons) and we all await a picture of him in his tuxedo! Sapna and James go on to discuss the 5-year outcomes of studies such as coBRIM, COMBI-d, and how those compare to 5-year benchmarks from the COLUMBUS study. They explore subgroups and characteristics of favorable (and durable) response, the role of MEK inhibitors on immune activation, and a potential fellow's project (looking at you, Rob?). Keywords Melanoma, targeted therapy, co-BRIM, COMBI-d, COLUMBUS, immunotherapy, BRAF MEK inhibitors, overall survival, progression-free survival, patient outcomes, cohorts, LDH, organ sites Takeaways MEK inhibitors have a complex role in immune response. Normal LDH levels correlate with better patient outcomes. Immunotherapy and targeted therapy can have overlapping patient populations. Sound Bites "We thought we'd do more targeted therapy" "Normal LDH is doing better." "Long-term follow-up for targeted therapy." Chapters 00:00 Will he or won't he ... James awaits invitation to film premiere 04:26 coBRIM 5y FU 11:56 COMBI-d 5y FU 13:19 LDH subgroups 17:26 Normal LDH & 3 organ sites of metastasis 18:07 Invalid analysis & graph ... tsk tsk NEJM 22:36 Fact Check 22:40 What's the color of James' t-shirt? 25:34 Five-Year Results of BRAF Targeted Therapies 28:37 Cure Potential of Adjuvant Targeted Therapy 31:34 MEK Inhibition and Immune Activation
Ep 78 TRAILER: MEK inhibitor trials
2025/12/29
Enjoy this short trailer on MEK inhibitor monotherapy trials in melanoma

Podcast reviews

Read Melanoma Matters podcast reviews


4 out of 5
4 reviews

Podcast sponsorship advertising

Start advertising on Melanoma Matters relevant audience podcasts


What do you want to promote?